Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. SAVE Investigators
P Vantrimpont,
JL Rouleau,
CC Wun,
A Ciampi,
M Klein,
B Sussex,
JM Arnold,
L Moye,
and
M Pfeffer
Department of Medicine, Montreal Heart Institute, Quebec, Canada.
OBJECTIVES: This study assessed whether treatment with a beta-adrenergic blocking agent in addition to the use of the angiotensin-converting enzyme (ACE) inhibitor captopril decreases cardiovascular mortality and morbidity in patients with asymptomatic left ventricular dysfunction after myocardial infarction (MI) and whether the presence of neurohumoral activation at the time of hospital discharge predicts the effects of beta-blocker treatment in these patients. BACKGROUND: Both beta-blockers and ACE inhibitors have been shown to have beneficial effects in patients with left ventricular dysfunction but no overt heart failure after MI. These patients often have persistent neurohumoral activation at the time of hospital discharge, and one would expect that patients with activation of the sympathetic nervous system derive the most benefit from treatment with beta-blockers. However, beta-blockers are underutilized in this high risk group of patients, and it is unknown whether their beneficial effects are additive to those of ACE inhibitors. METHODS: We performed a retrospective analysis of data from the Survival and Ventricular Enlargement (SAVE) study and its neurohumoral substudy. The relations between beta-blocker use at the time of randomization and neurohumoral activation and the subsequent development of cardiovascular events were analyzed by use of Cox proportional hazards models controlling for covariates. RESULTS: After adjustment for baseline imbalances, beta-blocker use was associated with a significant reduction in risk of cardiovascular death (30%, 95% confidence interval [CI] 12% to 44%) and development of heart failure (21%, 95% CI 3% to 36%), but the reduction in recurrent MI (11%, 95% CI 13% to 31%) was not significant. These reductions were independent of the use of captopril. Beta-blockers were not found to have a greater effect in patients with neurohumoral activation at the time of hospital discharge. CONCLUSIONS: The beneficial effects of beta-blocker use at the time of hospital discharge in patients with asymptomatic left ventricular dysfunction after MI appear to be additive to those of captopril and other interventions known to improve prognosis. Neurohumoral activation at the time of hospital discharge fails to identify those patients who will derive the greatest benefit from treatment with beta-blockers.
This article has been cited by other articles:
|
|
|
|
 
M. Klapholz
{beta}-Blocker Use for the Stages of Heart Failure
Mayo Clin. Proc.,
August 1, 2009;
84(8):
718 - 729.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. A. Hunt, W. T. Abraham, M. H. Chin, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. Jessup, M. A. Konstam, D. M. Mancini, K. Michl, et al.
2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation
J. Am. Coll. Cardiol.,
April 14, 2009;
53(15):
e1 - e90.
[Full Text]
[PDF]
|
|
|
|
|
|
|
2005 WRITING COMMITTEE MEMBERS, S. A. Hunt, W. T. Abraham, M. H. Chin, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. Jessup, M. A. Konstam, D. M. Mancini, et al.
2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the International Society for Heart and Lung Transplantation
Circulation,
April 14, 2009;
119(14):
e391 - e479.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. D. Schocken, E. J. Benjamin, G. C. Fonarow, H. M. Krumholz, D. Levy, G. A. Mensah, J. Narula, E. S. Shor, J. B. Young, and Y. Hong
Prevention of Heart Failure: A Scientific Statement From the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group
Circulation,
May 13, 2008;
117(19):
2544 - 2565.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. M. Albert and C. Lewis
Recognizing and Managing Asymptomatic Left Ventricular Dysfunction: After Myocardial Infarction
Crit. Care Nurse,
April 1, 2008;
28(2):
20 - 37.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Ring, H. Persson, M. Mejhert, and M. Edner
Post-systolic motion in patients with heart failure - A marker of left ventricular dyssynchrony?
Eur J Echocardiogr,
October 1, 2007;
8(5):
352 - 359.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. N. Kirkpatrick, M. A. Vannan, J. Narula, and R. M. Lang
Echocardiography in Heart Failure: Applications, Utility, and New Horizons
J. Am. Coll. Cardiol.,
July 31, 2007;
50(5):
381 - 396.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Filippatos and D. T. Kremastinos
Beta-blockers in asymptomatic dilated cardiomyopathy: to b-block or not to b-block?
Eur. Heart J.,
May 1, 2007;
28(9):
1170 - 1171.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. A Howard, J. W. Cheng, M. A Crouch, V. J Colucci, J. S Kalus, S. A Spinler, and M. Munger
Drug Therapy Recommendations from the 2005 ACC/AHA Guidelines for Treatment of Chronic Heart Failure
Ann. Pharmacother.,
September 1, 2006;
40(9):
1607 - 1616.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. R. Goldberg and M. Jessup
Stage B Heart Failure: Management of Asymptomatic Left Ventricular Systolic Dysfunction
Circulation,
June 20, 2006;
113(24):
2851 - 2860.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Volpe, G. Tocci, and E. Pagannone
Fewer Mega-Trials and More Clinically Oriented Studies in Hypertension Research? The Case of Blocking the Renin-Angiotensin-Aldosterone System.
J. Am. Soc. Nephrol.,
April 1, 2006;
17(4_suppl_2):
S36 - S43.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. S. Aronow
Drug Treatment of Systolic and of Diastolic Heart Failure in Elderly Persons
J. Gerontol. A Biol. Sci. Med. Sci.,
December 1, 2005;
60(12):
1597 - 1605.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Developed in Collaboration With the American Colle, Endorsed by the Heart Rhythm Society, S. A. Hunt, W. T. Abraham, M. H. Chin, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. Jessup, M. A. Konstam, et al.
ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult--Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure)
J. Am. Coll. Cardiol.,
September 20, 2005;
46(6):
1116 - 1143.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. A. Hunt, W. T. Abraham, M. H. Chin, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. Jessup, M. A. Konstam, D. M. Mancini, K. Michl, et al.
ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult--Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration With the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: Endorsed by the Heart Rhythm Society
Circulation,
September 20, 2005;
112(12):
1825 - 1852.
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Hartmann, M. Packer, A. J.S. Coats, M. B. Fowler, H. Krum, P. Mohacsi, J. L. Rouleau, M. Tendera, A. Castaigne, S. D. Anker, et al.
Prognostic Impact of Plasma N-Terminal Pro-Brain Natriuretic Peptide in Severe Chronic Congestive Heart Failure: A Substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Trial
Circulation,
September 28, 2004;
110(13):
1780 - 1786.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. S. McKelvie, J.-L. Rouleau, M. White, R. Afzal, J. B. Young, A. P. Maggioni, P. Held, and S. Yusuf
Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodelling in patients with congestive heart failure
Eur. Heart J.,
October 1, 2003;
24(19):
1727 - 1734.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Waagstein, O. Stromblad, B. Andersson, M. Bohm, M. Darius, W. Delius, F. Goss, K.J. Osterziel, M. Sigmund, S.-P. Trenkwalder, et al.
Increased exercise ejection fraction and reversed remodeling after long-term treatment with metoprolol in congestive heart failure: a randomized, stratified, double-blind, placebo-controlled trial in mild to moderate heart failure due to ischemic or idiopathic dilated cardiomyopathy
Eur J Heart Fail,
October 1, 2003;
5(5):
679 - 691.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. J. Wang, D. Levy, E. J. Benjamin, and R. S. Vasan
The Epidemiology of "Asymptomatic" Left Ventricular Systolic Dysfunction: Implications for Screening
Ann Intern Med,
June 3, 2003;
138(11):
907 - 916.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D A Wood
Preventing clinical heart failure: the rationale and scientific evidence
Heart,
October 1, 2002;
88(90002):
ii15 - 22.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Gheorghiade and S. Goldstein
{beta}-Blockers in the Post-Myocardial Infarction Patient
Circulation,
July 23, 2002;
106(4):
394 - 398.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. H. Farrell, J. M. Foody, and H. M. Krumholz
{beta}-Blockers in Heart Failure: Clinical Applications
JAMA,
February 20, 2002;
287(7):
890 - 897.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. H Jagasia and K. Shivkumar
Carvedilol reduced mortality and morbidity caused by myocardial infarction in patients with left ventricular dysfunction
Evid. Based Med.,
January 1, 2002;
7(1):
15 - 15.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Galcera-Tomas, F. J. Castillo-Soria, M. Villegas-Garcia, R. Florenciano-Sanchez, J. G. Sanchez-Villanueva, J. A. N. de la Rosa, A. Martinez-Caballero, J. A. Valenti-Aldeguer, P. Jara-Perez, M. Parraga-Ramirez, et al.
Effects of Early Use of Atenolol or Captopril on Infarct Size and Ventricular Volume : A Double-Blind Comparison in Patients With Anterior Acute Myocardial Infarction
Circulation,
February 13, 2001;
103(6):
813 - 819.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Geraci and A. A. Knowlton
Spironolactone for Heart Failure : Spiraling Out of Control
Chest,
December 1, 2000;
118(6):
1522 - 1523.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Taniyama, R. Morishita, H. Nakagami, A. Moriguchi, H. Sakonjo, Shokei-Kim, K. Matsumoto, T. Nakamura, J. Higaki, and T. Ogihara
Potential Contribution of a Novel Antifibrotic Factor, Hepatocyte Growth Factor, to Prevention of Myocardial Fibrosis by Angiotensin II Blockade in Cardiomyopathic Hamsters
Circulation,
July 11, 2000;
102(2):
246 - 252.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Effects of Metoprolol CR in Patients With Ischemic and Dilated Cardiomyopathy : The Randomized Evaluation of Strategies for Left Ventricular Dysfunction Pilot Study
Circulation,
February 1, 2000;
101(4):
378 - 384.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S Capewell, J.P Pell, C Morrison, and J McMurray
Increasing the impact of cardiological treatments. How best to reduce deaths
Eur. Heart J.,
October 1, 1999;
20(19):
1386 - 1392.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C. M. Kramer, P. D. Nicol, W. J. Rogers, P. S. Seibel, C. S. Park, and N. Reichek
beta -Blockade improves adjacent regional sympathetic innervation during postinfarction remodeling
Am J Physiol Heart Circ Physiol,
October 1, 1999;
277(4):
H1429 - H1434.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. V. Exner, D. L. Dries, M. A. Waclawiw, B. Shelton, and M. J. Domanski
Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the studies of left ventricular dysfunction
J. Am. Coll. Cardiol.,
March 15, 1999;
33(4):
916 - 923.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Richards, R. Doughty, M. G. Nicholls, S. Macmahon, H. Ikram, N. Sharpe, E. A. Espiner, C. Frampton, and T. G. Yandle
Neurohumoral Prediction of Benefit From Carvedilol in Ischemic Left Ventricular Dysfunction
Circulation,
February 16, 1999;
99(6):
786 - 792.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K S Spargias, A S Hall, D C Greenwood, and S G Ball
beta Blocker treatment and other prognostic variables in patients with clinical evidence of heart failure after acute myocardial infarction: evidence from the AIRE study
Heart,
January 1, 1999;
81(1):
25 - 32.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
N. L. Smith, G. E. Reiber, B. M. Psaty, S. R. Heckbert, D. S. Siscovick, J. L. Ritchie, N. R. Every, and T. D. Koepsell
Health outcomes associated with beta-blocker and diltiazem treatment of unstable angina
J. Am. Coll. Cardiol.,
November 1, 1998;
32(5):
1305 - 1311.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M Martin, N. R Dunn, S. N Freemantle, and R. D Mann
Risk of non-fatal cardiac failure and ischaemic heart disease with long acting beta 2 agonists
Thorax,
July 1, 1998;
53(7):
558 - 562.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
R. P Steeds and K. S Channer
Drug treatment in heart failure
BMJ,
February 14, 1998;
316(7131):
567 - 568.
[Full Text]
|
|
|
|
|
|
|
L. Mosca, J. E. Manson, S. E. Sutherland, R. D. Langer, T. Manolio, E. Barrett-Connor, and E. Barrett-Connor
Cardiovascular Disease in Women : A Statement for Healthcare Professionals From the American Heart Association
Circulation,
October 7, 1997;
96(7):
2468 - 2482.
[Full Text]
|
|
|
|
|
|
|
A. D. Michaels, G. Gambassi, P. Carbonin, R. Bernabei, E. Loh, L. A. Moye, and M. A. Pfeffer
Risk of Stroke after Myocardial Infarction
N. Engl. J. Med.,
June 26, 1997;
336(26):
1916 - 1917.
[Full Text]
|
|
|
|
|
|
|
Beta-Blockers Add Benefits After MI
Journal Watch Cardiology,
March 11, 1997;
1997(311):
1 - 1.
[Full Text]
|
|
|
|
